Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity

Amstutz, Ursula; Froehlich, Tanja K; Largiadèr, Carlo R (2011). Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics, 12(9), pp. 1321-36. London: Future Medicine 10.2217/PGS.11.72

Full text not available from this repository. (Request a copy)

The importance of polymorphisms in the dihydropyrimidine dehydrogenase (DPD) gene (DPYD) for the prediction of severe toxicity in 5-fluorouracil (5-FU) based chemotherapy has been controversially debated. As a key enzyme in the catabolism of 5-FU, DPD is the top candidate for pharmacogenetic studies on 5-FU toxicity, since a reduced DPD activity is thought to result in an increased half-life of the drug, and thus, an increased risk of toxicity. Here, we review the current knowledge on well-known and frequently studied DPYD variants such as the c.1905+1G>A splice site variant, as well as the recent discoveries of important functional variation in the noncoding regions of DPYD. We also outline future directions that are needed to further improve the risk assessment of 5-FU toxicity, in particular with respect to metabolic profiling and in the context of different combination therapeutic regimens, in which 5-FU is used today.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Institute of Clinical Chemistry

UniBE Contributor:

Fröhlich, Tanja and Largiadèr, Carlo Rodolfo

ISSN:

1462-2416

Publisher:

Future Medicine

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 14:22

Last Modified:

06 Dec 2013 13:28

Publisher DOI:

10.2217/PGS.11.72

PubMed ID:

21919607

Web of Science ID:

000295728800018

URI:

https://boris.unibe.ch/id/eprint/7577 (FactScience: 212871)

Actions (login required)

Edit item Edit item
Provide Feedback